
FDA postpones first-cycle review of Dysport Paris — French pharmaceutical company Ipsen says the U.S. Food and Drug Administration (FDA) will not complete its first-cycle review of Ipsen’s botulinum toxin type A product Dysport until the end of the year, Reuters reports. | ![]() Stay Connected to Dermatology Times • Current Issue • Issue Archive • Subscribe to Enewsletter • Subscribe to Print Edition • Subscribe to Digital Edition • DT Radio • Events Calendar • Follow Us on Twitter Coding Counselor Simple and accurate ICD-9 code search. Start Here Formulary Counselor Find health plan drug coverage in your area. Start Here Patient Education Print customized patient education handouts. Start Here Surgical Video Center On-demand surgery demos and presentations. Start Here ![]() ![]() Featured Jobs |